Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41401-021-00668-7 http://scihub22266oqcxt.onion/10.1038/s41401-021-00668-7 33907306!8076879!33907306     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Acta+Pharmacol+Sin 2022 ; 43 (2): 483-493 Nephropedia Template TP {{tp|p=33907306|t=2022. A multi-targeting drug design strategy for identifying potent anti-SARS-CoV-2 inhibitors |pdf=|usr=}}{{33907306}} gab.com Text A multi-targeting drug design strategy for identifying potent anti-SARS-CoV-2 inhibitors JO: Acta Pharmacol Sin http://www.kidney.de/pget.php?&tw=1&pmid=33907306 #FOAvip The COVID-19, caused by SARS-CoV-2, is threatening public health, and there is no effective treatment. In this study, we have implemented a multi-targeted anti-viral drug design strategy to discover highly potent SARS-CoV-2 inhibitors, which simultaneously act on the host ribosome, viral RNA as well as RNA-dependent RNA polymerases, and nucleocapsid protein of the virus, to impair viral translation, frameshifting, replication, and assembly. Driven by this strategy, three alkaloids, including lycorine, emetine, and cephaeline, were discovered to inhibit SARS-CoV-2 with EC(50) values of low nanomolar levels potently. The findings in this work demonstrate the feasibility of this multi-targeting drug design strategy and provide a rationale for designing more potent anti-virus drugs. Twit Text FOAVip A multi-targeting drug design strategy for identifying potent anti-SARS-CoV-2 inhibitors ????Acta Pharmacol Sin http://www.kidney.de/pget.php?&tw=1&pmid=33907306 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33907306 #FOAvip English Wikipedia <ref>{{Cite pmid|33907306}}</ref> A multi-targeting drug design strategy for identifying potent anti-SARS-CoV-2 inhibitors #MMPMID33907306 Ren PX; Shang WJ; Yin WC; Ge H; Wang L; Zhang XL; Li BQ; Li HL; Xu YC; Xu EH; Jiang HL; Zhu LL; Zhang LK; Bai F Acta Pharmacol Sin 2022[Feb]; 43 (2): 483-493 PMID33907306show ga The COVID-19, caused by SARS-CoV-2, is threatening public health, and there is no effective treatment. In this study, we have implemented a multi-targeted anti-viral drug design strategy to discover highly potent SARS-CoV-2 inhibitors, which simultaneously act on the host ribosome, viral RNA as well as RNA-dependent RNA polymerases, and nucleocapsid protein of the virus, to impair viral translation, frameshifting, replication, and assembly. Driven by this strategy, three alkaloids, including lycorine, emetine, and cephaeline, were discovered to inhibit SARS-CoV-2 with EC(50) values of low nanomolar levels potently. The findings in this work demonstrate the feasibility of this multi-targeting drug design strategy and provide a rationale for designing more potent anti-virus drugs. |*Drug Design[MESH] |Animals[MESH] |Antiviral Agents/chemical synthesis/chemistry/*pharmacology[MESH] |Cell Line[MESH] |Chlorocebus aethiops[MESH] |Dose-Response Relationship, Drug[MESH] |Humans[MESH] |Microbial Sensitivity Tests[MESH] |Molecular Structure[MESH] |SARS-CoV-2/*drug effects[MESH]A multi-targeting drug design strategy for identifying potent anti-SAR(epmc).pdf DeepDyve Pubget Overpricing